STOCK TITAN

Royalty Pharma plc (RPRX) DEF 14A Filings

RPRX NASDAQ

Here are the DEF 14A proxy statements from Royalty Pharma plc (RPRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPRX filings page.

Rhea-AI Summary

Royalty Pharma plc is asking shareholders to vote at its 2026 Annual General Meeting on June 4, 2026 in New York. Items include electing nine directors, advisory votes on U.S. and U.K. executive pay, auditor ratifications, authority to repurchase Class A shares, and approvals to allot shares with and without pre-emption rights.

The company highlights 2025 performance with $3.3BN in portfolio receipts, $3.0BN in adjusted EBITDA, $2.7BN in portfolio cash flow, and $4.7BN in announced transaction value. It returned over $1.7BN to shareholders, including more than $1.2BN of buybacks, while deploying $2.6BN into royalty acquisitions.

Royalty Pharma completed internalization of its external manager, emphasizing stronger board oversight of compensation and succession. The largely independent, skills-diverse board—led by Chairman and CEO Pablo Legorreta and Lead Independent Director Ted Love—stresses pay-for-performance, robust share ownership guidelines, risk oversight, and corporate responsibility initiatives around responsible investment, human capital, and sustainability.